{
  "main_header": {
    "sid": 134395,
    "name": "Jenburkt Pharma",
    "stock_name": "Jenburkt Pharma",
    "full_name": "Jenburkt Pharmaceuticals Ltd.",
    "name_url": "stocks-analysis/jenburkt-pharma",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "1,179.80",
    "chg": 30.9,
    "chgp": "2.69%",
    "dir": 1,
    "prev_price": "1,148.90",
    "mcapval": "509.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 524731,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "India SENSEX",
    "isin": "INE354A01013",
    "curr_date": "Jun 18",
    "curr_time": "",
    "bse_nse_vol": "913 ",
    "exc_status": "Active",
    "traded_date": "Jun 18, 2026",
    "traded_date_str": "2026 06 18",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://marketsmojo.motilaloswaluat.com/MOSL-Landingstocks-analysis/jenburkt-pharma-134395-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [],
    "total": 480,
    "sid": "134395",
    "stock_news_url": "https://marketsmojo.motilaloswaluat.com/news/jenburkt-pharmaceuticals-134395"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "27-May-2026",
      "details": "Newspaper Advertisement for giving notice for the purpose of transfer of unclaimed dividend and corresponding equity shares of the Company to IEPFA.",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Intimation for Taking On Record The Audited Financial Results For The Quarter And Financial Year Ended On 31St March 2026 And To Consider Recommendation Of Dividend If Any.",
      "datetime": "28-Apr-2026",
      "details": "Jenburkt Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/05/2026 inter alia to consider and approve the audited results for the quarter and financial year ended on 31st March 2026 and to consider recommendation of dividend if any.",
      "source": "BSE"
    },
    {
      "caption": "Disclosures Pursuant To SEBI Circular Dated 10Th August 2021 :Not A Large Corporate",
      "datetime": "14-Apr-2026",
      "details": "Pursuant to SEBI Circular dated 10th August 2021 we hereby confirm that for the financial year ended 31st March 2026 Jenburkt pharmaceuticals Limited is not a large corporate as per applicability criteria mentioned in clause 2.11 of chapter XII therein.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Jenburkt Pharmaceuticals Ltd. has declared <strong>180%</strong> dividend, ex-date: 11 Jul 25",
          "dt": "2025-07-11",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

No Recent News for the Company

View All News